Abstract
The expression of the p170 multidrug resistance protein by bone marrow plasma cells (BMPC) was assessed at clinical presentation in 53 patients with multiple myeloma (MM) using the C219 monoclonal antibody. Twenty-two of the 53 (41 per cent) patients had variable aliquots (1-60 per cent, median = 6 per cent) of p170 + BMPC by immunocytochemistry. Five of 10 patients studied using bivariate flow cytometry had both diploid and hyperdiploid (DNA index ranged from 1.2 to 1.5) BMPC with hyperdiploid clones having significantly greater p170 expression than diploid ones. Of the 37 patients evaluated for a response, 20 (54 per cent) had responded to induction chemotherapy. The presence of p170 + BMPC was a negative indicator for achieving response. The response rate was 75 per cent for p170- and 25 per cent for p170+ cases (p <0.01), with no difference on the basis of treatment schedule (melphalan and prednisone, 24 patients; peptichemio, vincristine and prednisone, 13 patients). No difference in response and survival duration was found between p170+ and p170- patients. In six of nine patients studied both at diagnosis and folllowing induction chemotherapy the p170+ BMPC% increased irrespective of the type of treatment or outcome.
| Original language | English |
|---|---|
| Pages (from-to) | 213-220 |
| Number of pages | 8 |
| Journal | Hematological Oncology |
| Volume | 10 |
| Issue number | 3-4 |
| DOIs | |
| Publication status | Published - 1992 |
Fingerprint
Keywords
- Myeloma
- p170
- Therapy
ASJC Scopus subject areas
- Cancer Research
- Hematology
- Oncology
Cite this
Expression of p170 protein in multiple myeloma : A clinical study. / Ucci, G.; Petrini, M.; Riccardi, A.; Invernizzi, R.; Carulli, G.; Luoni, R.; Giordano, M.; Danova, M.
In: Hematological Oncology, Vol. 10, No. 3-4, 1992, p. 213-220.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Expression of p170 protein in multiple myeloma
T2 - A clinical study
AU - Ucci, G.
AU - Petrini, M.
AU - Riccardi, A.
AU - Invernizzi, R.
AU - Carulli, G.
AU - Luoni, R.
AU - Giordano, M.
AU - Danova, M.
PY - 1992
Y1 - 1992
N2 - The expression of the p170 multidrug resistance protein by bone marrow plasma cells (BMPC) was assessed at clinical presentation in 53 patients with multiple myeloma (MM) using the C219 monoclonal antibody. Twenty-two of the 53 (41 per cent) patients had variable aliquots (1-60 per cent, median = 6 per cent) of p170 + BMPC by immunocytochemistry. Five of 10 patients studied using bivariate flow cytometry had both diploid and hyperdiploid (DNA index ranged from 1.2 to 1.5) BMPC with hyperdiploid clones having significantly greater p170 expression than diploid ones. Of the 37 patients evaluated for a response, 20 (54 per cent) had responded to induction chemotherapy. The presence of p170 + BMPC was a negative indicator for achieving response. The response rate was 75 per cent for p170- and 25 per cent for p170+ cases (p <0.01), with no difference on the basis of treatment schedule (melphalan and prednisone, 24 patients; peptichemio, vincristine and prednisone, 13 patients). No difference in response and survival duration was found between p170+ and p170- patients. In six of nine patients studied both at diagnosis and folllowing induction chemotherapy the p170+ BMPC% increased irrespective of the type of treatment or outcome.
AB - The expression of the p170 multidrug resistance protein by bone marrow plasma cells (BMPC) was assessed at clinical presentation in 53 patients with multiple myeloma (MM) using the C219 monoclonal antibody. Twenty-two of the 53 (41 per cent) patients had variable aliquots (1-60 per cent, median = 6 per cent) of p170 + BMPC by immunocytochemistry. Five of 10 patients studied using bivariate flow cytometry had both diploid and hyperdiploid (DNA index ranged from 1.2 to 1.5) BMPC with hyperdiploid clones having significantly greater p170 expression than diploid ones. Of the 37 patients evaluated for a response, 20 (54 per cent) had responded to induction chemotherapy. The presence of p170 + BMPC was a negative indicator for achieving response. The response rate was 75 per cent for p170- and 25 per cent for p170+ cases (p <0.01), with no difference on the basis of treatment schedule (melphalan and prednisone, 24 patients; peptichemio, vincristine and prednisone, 13 patients). No difference in response and survival duration was found between p170+ and p170- patients. In six of nine patients studied both at diagnosis and folllowing induction chemotherapy the p170+ BMPC% increased irrespective of the type of treatment or outcome.
KW - Myeloma
KW - p170
KW - Therapy
UR - http://www.scopus.com/inward/record.url?scp=0026743233&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026743233&partnerID=8YFLogxK
U2 - 10.1002/hon.2900100312
DO - 10.1002/hon.2900100312
M3 - Article
VL - 10
SP - 213
EP - 220
JO - Hematological Oncology
JF - Hematological Oncology
SN - 0278-0232
IS - 3-4
ER -